Karin Rennstam

Summary

Affiliation: Lund University
Country: Sweden

Publications

  1. ncbi Comparison of cisplatin sensitivity and the 18F fluoro-2-deoxy 2 glucose uptake with proliferation parameters and gene expression in squamous cell carcinoma cell lines of the head and neck
    Eva Henriksson
    Department of Otorhinolaryngology, University Hospital Malmo, SE 205 02 Malmo, Sweden
    J Exp Clin Cancer Res 28:17. 2009
  2. ncbi High-throughput genomic technology in research and clinical management of breast cancer. Molecular signatures of progression from benign epithelium to metastatic breast cancer
    Karin Rennstam
    Department of Oncology, Clinical Sciences, Lund University, Lund, Sweden
    Breast Cancer Res 8:213. 2006
  3. ncbi Cytogenetic characterization and gene expression profiling of the trastuzumab-resistant breast cancer cell line JIMT-1
    Karin Rennstam
    Department of Oncology, Clinical Sciences, Lund University, Barngatan 2 1, SE 221 85 Lund, Sweden
    Cancer Genet Cytogenet 172:95-106. 2007
  4. ncbi Patterns of chromosomal imbalances defines subgroups of breast cancer with distinct clinical features and prognosis. A study of 305 tumors by comparative genomic hybridization
    Karin Rennstam
    Jubileum Institute, Department of Oncology, University Hospital, Lund, Swedenland
    Cancer Res 63:8861-8. 2003
  5. ncbi Numb protein expression correlates with a basal-like phenotype and cancer stem cell markers in primary breast cancer
    Karin Rennstam
    Department of Oncology, Clinical Sciences, Lund University, Barngatan 2B, 221 85, Lund, Sweden
    Breast Cancer Res Treat 122:315-24. 2010
  6. ncbi Amplification of the cyclin D1 gene is associated with tumour subsite, DNA non-diploidy and high S-phase fraction in squamous cell carcinoma of the head and neck
    Emma Niméus
    Department of Oncology, University Hospital of Lund, SE 22185 Lund, Sweden
    Oral Oncol 40:624-9. 2004
  7. ncbi Genomic alterations in histopathologically normal breast tissue from BRCA1 mutation carriers may be caused by BRCA1 haploinsufficiency
    Karin Rennstam
    Department of Oncology, Clinical Sciences, Lund University, Lund, Sweden
    Genes Chromosomes Cancer 49:78-90. 2010
  8. ncbi Characterization of a novel breast carcinoma xenograft and cell line derived from a BRCA1 germ-line mutation carrier
    Oskar T Johannsson
    Departments of Oncology, University Hospital, Lund, Sweden
    Lab Invest 83:387-96. 2003

Detail Information

Publications8

  1. ncbi Comparison of cisplatin sensitivity and the 18F fluoro-2-deoxy 2 glucose uptake with proliferation parameters and gene expression in squamous cell carcinoma cell lines of the head and neck
    Eva Henriksson
    Department of Otorhinolaryngology, University Hospital Malmo, SE 205 02 Malmo, Sweden
    J Exp Clin Cancer Res 28:17. 2009
    ....
  2. ncbi High-throughput genomic technology in research and clinical management of breast cancer. Molecular signatures of progression from benign epithelium to metastatic breast cancer
    Karin Rennstam
    Department of Oncology, Clinical Sciences, Lund University, Lund, Sweden
    Breast Cancer Res 8:213. 2006
    ..This review provides a brief summary of recent progress in identifying molecular markers for invasiveness in early breast lesions...
  3. ncbi Cytogenetic characterization and gene expression profiling of the trastuzumab-resistant breast cancer cell line JIMT-1
    Karin Rennstam
    Department of Oncology, Clinical Sciences, Lund University, Barngatan 2 1, SE 221 85 Lund, Sweden
    Cancer Genet Cytogenet 172:95-106. 2007
    ..We conclude that cytogenetic and expression profiling of JIMT-1 revealed several new features that need further characterization and may shed light on trastuzumab resistance...
  4. ncbi Patterns of chromosomal imbalances defines subgroups of breast cancer with distinct clinical features and prognosis. A study of 305 tumors by comparative genomic hybridization
    Karin Rennstam
    Jubileum Institute, Department of Oncology, University Hospital, Lund, Swedenland
    Cancer Res 63:8861-8. 2003
    ..We conclude that patterns of copy number gains and losses define breast tumors with distinct clinicopathological features and patient prognosis...
  5. ncbi Numb protein expression correlates with a basal-like phenotype and cancer stem cell markers in primary breast cancer
    Karin Rennstam
    Department of Oncology, Clinical Sciences, Lund University, Barngatan 2B, 221 85, Lund, Sweden
    Breast Cancer Res Treat 122:315-24. 2010
    ..01). Taken together, our results indicate that loss of Numb expression is a marker of tumor aggressiveness, potentially linked to BRCA1 status and a cancer stem cell phenotype in primary breast cancer...
  6. ncbi Amplification of the cyclin D1 gene is associated with tumour subsite, DNA non-diploidy and high S-phase fraction in squamous cell carcinoma of the head and neck
    Emma Niméus
    Department of Oncology, University Hospital of Lund, SE 22185 Lund, Sweden
    Oral Oncol 40:624-9. 2004
    ..002 and p = 0.002, respectively). In conclusion, the rate of CCND1 amplification differed between different subsites in SCCHN and was also associated to a more aggressive tumour phenotype, as defined by DNA non-diploidy and high SPF...
  7. ncbi Genomic alterations in histopathologically normal breast tissue from BRCA1 mutation carriers may be caused by BRCA1 haploinsufficiency
    Karin Rennstam
    Department of Oncology, Clinical Sciences, Lund University, Lund, Sweden
    Genes Chromosomes Cancer 49:78-90. 2010
    ..Finding molecular markers of tumor initiation and progression, for the potential use in early disease detection, may be of great clinical importance for the improved management of at-risk women...
  8. ncbi Characterization of a novel breast carcinoma xenograft and cell line derived from a BRCA1 germ-line mutation carrier
    Oskar T Johannsson
    Departments of Oncology, University Hospital, Lund, Sweden
    Lab Invest 83:387-96. 2003
    ..We conclude that L56Br-X1 and L56Br-C1 are useful model systems for studies of the pathogenesis and new therapeutic modalities of BRCA1-induced human breast cancer...